ABSTRACT
on T cell proliferation and effector functions in tissue microenvironments (13) (14) (15) . IDO-mediated tryptophan metabolism, not only in APCs but also in tumor cells, represents a vital mechanism for potential T cell suppression during tumor growth (16) . Our previous study indicated that exposure to the milieu created by an IDO-positive NPC cell line significantly impaired lymphocyte cytotoxicity against target tumor cells (17) .
IDO expression is induced in macrophages and several other cell types under various physiological conditions, such as inflammation induced by viral and bacterial infections (18) . Infection with dengue virus, HIV, poliovirus, and hepatitis C virus is associated with IDO induction in various tissues and cell types, both in vivo and in vitro (19) (20) (21) (22) . Previously reported evidence suggests that EBV infection increases the expression level of IDO in B cells and inhibits NK cell cytotoxicity (23) . To date, whether IDO can be induced by EBV-infected macrophages and what effects EBV induction of IDO may have on macrophage immune functions have not been investigated.
To elucidate the potential role of IDO in macrophages during EBV infection, we investigated the signaling mechanisms by which EBV infection induces IDO expression in human monocyte-derived macrophages (MDMs) and the possible role of EBVmediated IDO induction in creating a microenvironment of suppressed T cell immune responses in MDMs.
MATERIALS AND METHODS
Cell culture. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque Plus gradient centrifugation of leukopacks derived from 25 healthy adult volunteers. Informed consent was obtained from the volunteers prior to participation, in accordance with the human experimentation guidelines of the Institute Research Ethics Committee of the Cancer Centre, Sun Yat-Sen University. CD14 ϩ monocytes were isolated from PBMCs by using magnetic CD14 microbeads (Miltenyi Biotech) according to the manufacturer's instructions. CD14 ϩ cells were matured into MDMs by 8 to 12 days in medium with 25 ng/ml macrophage colonystimulating factor (M-CSF) (R&D Systems). The isolation of CD4 ϩ and CD8 ϩ T lymphocytes from PBMCs was performed by means of immunomagnetic bead separation using a Dynal CD4-or CD8-positive isolation kit (Invitrogen Dynal). The purity of CD4 ϩ and CD8 ϩ cells was Ͼ98%, as determined by flow cytometry. CNE2 (human NPC cell line) and B95-8 (EBV-positive B cell line) cells were maintained in our laboratory. All of these cells were grown in complete RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (HyClone), 100 g/ml streptomycin, and 100 U/ml penicillin under a humidified 5% CO 2 atmosphere at 37°C in a CO 2 incubator.
EBV preparation and cell treatment. EBV was purified from B95-8 cell culture supernatants as previously described (24) . In brief, virus was propagated by inducing B95-8 cells with 30 ng/ml phorbol myristate acetate (PMA) and 4 mM butyric acid (both from Sigma) for 3 days. The virus was then pelleted by ultracentrifugation at 150,000 rpm for 90 min, filtered through a 0.8-mm pore size filter, and stored at Ϫ80°C. Viral titers were evaluated and adjusted to 2 ϫ 10 7 transforming units (TFU)/ml. Where indicated, virus stocks were inactivated by pretreatment with 9 mJ of UV radiation with a Stratalinker instrument, which completely abolished their ability to infect cells.
For the preparation of conditioned medium (CM), MDM cells were seeded at 5 ϫ 10 5 cells/ml for 24 h. Next, cells were infected with EBV or UV-irradiated EBV (UV-EBV) at various TFU/ml values for the indicated times. In certain experiments, 100 M 1-methyl-L-tryptophan (1-MT) (Sigma-Aldrich) was added to the medium. Subsequently, the culture supernatants were harvested as CM and stored in aliquots at Ϫ80°C before use.
For antibody-blocking experiments, MDMs were preincubated with 10 g/ml of neutralizing antibodies against tumor necrosis factor alpha (TNF-␣) ( (17) and a mouse monoclonal anti-CD68 antibody (1:100; BD Pharmingen) were incubated with tissue sections overnight at 4°C. After washing, tissue sections were treated with biotinylated anti-mouse or anti-rabbit antibody (Zymed), followed by further incubation with the streptavidin-horseradish peroxidase (HRP) conjugate. For immunofluorescence, tissue sections or MDM cells were incubated with antibodies against IDO (1:200) or CD68-phycoerythrin (PE) (1:100; BD Pharmingen) or the serum of a NPC patient who was positive for the EBV antibody (1:100) (viral capsid antigen [VCA]-IgA titer of 1:1,280, as determined by an immunofluorescence assay) at 4°C overnight. After washing, the slides were incubated with fluorescein isothiocyanate (FITC)-conjugated secondary antibodies (1:1,000; Abcam) or Alexa Fluor 594-conjugated antihuman IgG1 antibodies (1:1,000; BD Biosciences), and the cell nuclei were stained with 4=,6-diamidino-2-phenylindole (DAPI) (Sigma). The number of CD68 ϩ and IDO ϩ cells in the tumor stroma was counted. The mean values were derived from a visual analysis of 10 high-power fields (HPFs) (magnification, ϫ400), using a Nikon Eclipse E-200 microscope, which corresponded to an area of 0.5 mm 2 per HPF. Flow cytometry. CD14 ϩ cells were separated from PBMCs by the use of magnetic CD14 microbeads (Miltenyi Biotech). MDMs were generated from CD14 ϩ cells in the presence of M-CSF. MDMs were infected with EBV at 0.2 ϫ 10 5 TFU/ml, infected with UV-irradiated EBV, or not infected with EBV for 48 h. Cells were fixed for 10 min in 1% paraformaldehyde and then permeabilized with 1% saponin (BD Pharmingen). A FACScalibur instrument (Becton, Dickinson) and CellQuest software (Becton, Dickinson) were used for flow cytometric analysis. Monoclonal antibodies (MAbs) were obtained from BD Pharmingen, including anti-CD3-FITC, -CD4-FITC, -CD8-PE, -CD14-FITC, -CD19-PE, -CD21-FITC, -CD68-PE, -CD163-PE, and CD206-PE antibodies. The serum of a NPC patient who was positive for the EBV antibody (1:100) (VCA-IgA titer of 1:1,280, as determined by an immunofluorescence assay) and Alexa Fluor 594-conjugated goat anti-human IgG1 antibodies (BD Biosciences) were used to detect EBV infection. A rabbit polyclonal anti-IDO antibody (homemade) and goat anti-rabbit IgG1-FITC (Abcam) were used to detect IDO expression. Negative controls included isotypematched antibodies (BD Pharmingen) and normal human serum (VCAIgG negative, as determined by an immunofluorescence assay), which was treated as a control for detection of EBV infection.
Immunoblotting. Total protein extracts were prepared from MDM cells after treatment for the indicated time intervals. IDO was detected by using an anti-IDO polyclonal antibody (1:1,000). Mouse monoclonal antibody to EBV latent membrane protein 1 (LMP1) (1:1,000; Abcam), BZLF1 antibody (1:2,000; Millipore), and EBV nuclear antigen 1 (EBNA1) antibody (1:1,000; Santa Cruz Biotech) were used to detect EBV protein expression in MDMs. An anti-␤-tubulin monoclonal antibody (1:5,000; Abcam) was used to confirm equal loading.
To examine the activation of mitogen-activated protein kinase (MAPK), PI3K, and NF-B pathways, cell lysates were prepared from MDMs infected with EBV at 2 ϫ 10 5 TFU/ml or without EBV infection and probed with specific antibodies against individual components of these pathways (all antibodies were obtained from Cell Signaling). The active forms of the three MAPKs (p38, JNK, and ERK), Akt (a downstream target of PI3K), and the p65 and IB␣ subunits of the NF-B complex were detected with rabbit monoclonal antibodies to phosphorylated p38 (Thr180/Tyr1824), JNK (Thr183/Tyr185), ERK (Thr202Tyr204), Akt (Ser473), IB␣ (Ser32), and NF-B p65 (Ser536). The total amounts of MAPK, Akt, and NF-B proteins were analyzed with rabbit monoclonal antibodies to JNK, Akt, and NF-B p65; rabbit polyclonal antibodies to p38 and ERK; and a mouse monoclonal antibody to IB␣.
Quantitative PCR (qPCR). The total mRNA of the cells was extracted after treatment for the indicated times. First-strand cDNA synthesis was carried out by using 500 ng of total RNA. The quantification of target and reference (glyceraldehyde-3-phosphate dehydrogenase [GAPDH] ) genes was performed in triplicate by using a LightCycler 480 II instrument (Roche, Applied Science). The primers used for real-time PCR were as follows: forward primer 5=-GGCAAAGGTCATGGAGATGT-3= and reverse primer 5=-CTGCAGTCTCCATCACGAAA-3= for IDO and forward primer 5=-GCACCGTCAAGGCTGAGAAC-3= and reverse primer 5=-TG GTGAAGACGCCAGTGGA-3= for GAPDH.
Measurement of IDO activity. IDO activity was assayed according to a method described previously (17) . The cell culture medium was mixed with trichloroacetic acid and then centrifuged. Next, the supernatant was injected into a C 18 column and eluted with KH 2 PO 4 . The concentrations of tryptophan and kynurenine were analyzed by high-performance liquid chromatography (HPLC) (Waters). Tryptophan was measured by the detection of its native fluorescence at 285-nm excitation and 365-nm emission wavelengths. Kynurenines were detected by UV absorption at the 360-nm wavelength in the same chromatographic run, and the results were processed by using Waters Breeze software, version 3.30. IDO activity was determined by calculating the kynurenine-to-tryptophan (Kyn/ Trp) ratio (M/M).
Cell proliferation. CD4 ϩ and CD8 ϩ T cell proliferation was assessed by a standard thymidine incorporation assay. Briefly, 1 ϫ 10 5 cells were cultured in various CMs and stimulated with plate-bound anti-CD3 MAb (OKT3; ATCC) and soluble anti-CD28 MAb (BD Bioscience). After 72 h of culture, 1 Ci [ 3 H]thymidine was added, and incorporation was measured after 24 h with a ␤-Counter (Wallac).
EBV-specific cytotoxic T lymphocyte (CTL) assays against autologous EBV-transformed lymphoblastoid cell lines (EBV LCLs) were performed as described previously (25) . Briefly, 5 ϫ 10 6 to 10 ϫ 10 6 PBMCs from healthy donors were used for the establishment of an EBV LCL by infection of PBMCs with concentrated supernatants from the B95-8 working cell banks. EBV LCLs were used as the target cells. To generate EBVspecific CTLs, 2 ϫ 10 6 PBMCs/ml were cocultured with ␥-irradiated (40 Gy) autologous EBV LCLs. After 3 consecutive restimulations, the cultures were expanded in RPMI 1640 medium containing 20 U/ml recombinant human IL-2 (rhIL-2) (R&D Systems) and 10% fetal calf serum (FCS) medium. CD8 ϩ T lymphocytes, separated from the expanded bulk CTLs by anti-CD8 MAb-precoated Dynabeads (Invitrogen Dynal), were incubated in different CMs at 37°C for 5 h just before the cell-mediated cytotoxicity assay was performed and were used as the effector cells. The cytotoxic activity of CD8
ϩ CTLs in different CMs was evaluated in a standard 4-h 51 Cr release assay. The effector and target cells were adjusted to effector/T cell (E/T) ratios of 40:1, 20:1, and 10:1. Cytotoxicity was quantified by the measurement of 51 Cr release with a gamma counter (Beckman 9000; Beckman Coulter). The percentage of specific lysis was calculated as follows: 100 ϫ (total count/min in experimental wells Ϫ count/min of spontaneous release)/(count/min of maximum release Ϫ count/min of spontaneous release).
Cytokine analysis. The qualification of cytokines in CM was performed using a BD Cytometric Bead Array panel kit (BD Biosciences). The analytes included in the 8-plex kit were IL-1␤, IL-2, IL-4, IL-6, IL-8, IL-10, gamma interferon (IFN-␥), and TNF-␣. The 8 cytokines were measured by flow cytometry according to the manufacturer's instructions.
Statistical analysis. Paired t tests were used to analyze data, unless otherwise indicated. We report the nominal P value for each comparison without adjusting for multiple testing. Thus, these results should be interpreted cautiously due to the possible inflation of type 1 errors. A P value of Ͻ0.05 was considered to be statistically significant.
RESULTS
IDO expression in macrophages of NPC tissue. To investigate the exact expression level of IDO in vivo, IDO protein was detected by immunohistochemistry of paraffin-embedded archived NPC tissues. High IDO immunoreactivity was observed in NPC tissue ( Fig. 1A and B) . IDO localization was observed in the cytoplasm of some tumor cells. In addition, IDO staining was also observed in certain cells within the tumor stroma, and these cells exhibited stronger staining than did the cancer cells. To classify these IDOpositive cells in the tumor stroma, CD68 was detected by immunohistochemistry of NPC tissues. High CD68 expression levels were observed at the tumor stroma region (Fig. 1C and D) . Table 1) . These assays revealed that some macrophages in the tumor stroma region of NPC tissue express IDO.
EBV infection induces IDO expression in MDMs. As macrophages in NPC tissues express IDO, we investigated whether EBV infection altered IDO expression in macrophage cells. MDMs were generated from CD14 ϩ cells, in which CD3 T cells and CD19 B cells were not detectable ( Fig. 2A to C) . Figure 2D to G show that the phenotype of MDMs was CD14 high CD163 high CD206 medium CD68 positive . The level of CD21 expression was very low and was observed for only 2.3% of MDMs (Fig. 2H) . The lytic infection protein BZLF1 and the latent infection proteins EBNA1 and LMP1 were expressed in MDMs infected with EBV, whereas none of the three proteins were found in MDMs infected with UVirradiated EBV (UV-EBV) as well as in those without EBV infection (Fig. 2I) . IDO expression in MDMs infected with EBV and UV-EBV was assessed by qPCR and Western blot analysis, respectively. The IDO mRNA and protein assays showed that IDO can be induced in MDMs by infection with live EBV but not UV-EBV (Fig. 3A to D) . Infection with low-dose EBV (0.01 ϫ 10 5 TFU) for 48 h was able to induce IDO expression. The IDO level was further increased in a time-dependent manner, peaking at 48 h (Fig. 3A  and B) , and in a dose-dependent manner, peaking at 0.2 ϫ 10 5 TFU (Fig. 3C and D) . The enzymatic activity of IDO was also investigated by HPLC. The enzymatic activity of IDO was almost undetectable in the supernatant of MDMs infected with UV-EBV but was observed in cells infected with EBV ( Fig. 3E and F) . These results are consistent with the qPCR and Western blotting results. Using an EBV-positive serum (Fig. 3G) , about 54% (range, 52.1% to 56.7%) of MDMs were detected to be infected by EBV, and 47% of MDMs showed EBV infection and IDO expression by flow cytometric analysis. EBV infection and IDO expression were not detectable in MDMs infected with UV-irradiated EBV (Fig. 3H) . These results confirmed that EBV infection can induce IDO expression in human MDMs.
Involvement of IL-6 and TNF-␣ in induction of IDO by EBVMDMs. To investigate the cytokines that are involved in the induction of IDO in EBV-MDMs, cytokine concentrations were measured by using a cytokine bead array. As shown in Table 2 pg/ml at 48 h; IL-10, 9.3 Ϯ 1.8 versus 2.3 Ϯ 1.1 pg/ml at 48 h [P Ͻ 0.001]). TNF-␣ levels (13.2 Ϯ 2.4 pg/ml) and IL-6 levels (46.3 Ϯ 5.2 pg/ml) reached their peak at 48 h post-EBV infection; the IL-6 level was substantially elevated (Fig. 4A and B) . Given that TNF-␣ and IL-6 are potent inducers of IDO expression, we examined the possible involvement of these two cytokines in IDO expression induced by EBV infection using neutralizing antibody assays. Neutralizing antibodies against IL-6 and TNF-␣ significantly blocked the increased IDO expression level and enzyme activity induced by EBV-MDMs, and the combination of both antibodies almost completely blocked the induction of IDO protein and its enzyme activity (Fig. 4C and D) . These data indicate that EBV infection is able to induce several proinflammatory cytokines in MDMs, with the exception of IFN-␥, and the expression of IL-6 and TNF-␣ mediated by EBV infection is involved in the induction of IDO.
Role of MAPK and NF-B activation in expression of EBVinduced IDO, IL-6, and TNF-␣. Activation of the MAPK, PI3K, and NF-B signal transduction pathways is critical for IFN-␥-independent induction of IDO. We investigated whether EBV infection activates the MAPK (p38, JNK, and ERK), PI3K, and NF-B pathways in MDMs by Western blot analysis using antibodies against the phosphorylated forms of MAPK, Akt, and NF-B subunits. As shown in Fig. 5 , live EBV rapidly induced the phosphorylation of p38, JNK, ERK, and Akt, which generally peaked at approximately 30 to 90 min postinfection (Fig. 5A) . In resting cells, the p50 and p65 heterodimers of the transcription factor NF-B are sequestered in the cytoplasm by the IB protein.
NF-B activation involves the phosphorylation and subsequent degradation of IB and the phosphorylation of p65. EBV infection of MDMs led to an increase in the phosphorylation of IB␣ and p65 within 30 min. Synchronously, total IB␣ was degraded at between 30 and 120 min (Fig. 5B) . The requirement of these pathways for the EBV-induced expression of IDO was also assessed by using specific pharmacological inhibitors. As shown in Fig. 6A , compared to the DMSO vehicle control, the p38 MAPK inhibitor SB202190 significantly inhibited IDO mRNA expression. In contrast, The JNK inhibitor SP600125, the ERK inhibitor U0126, and the PI3K inhibitor wortmannin had little effect on IDO mRNA expression. Figure 6B and C show that SB202190 significantly inhibited IDO enzyme activity and protein production but that SP600125, U0126, and wortmannin did not. Compared to its inactive control, NF-B SN50M, and the vehicle control, the NF-B inhibitor SN50 significantly suppressed IDO mRNA expression, protein induction, and enzyme activities. Furthermore, the combination of SB202190 and SN50 nearly completely abolished the IDO produced by EBV-MDM cells (Fig. 6A to C) . Next, we examined the effects of these inhibitors on the production of TNF-␣ and IL-6, respectively. SB202190 and SN50 significantly decreased the induction of TNF-␣ and IL-6 compared to the vehicle control. Moreover, the combination of SB202190 and SN50 nearly completely abolished the production of TNF-␣ and IL-6 ( Fig. 6D and  E) . These results revealed that p38 MAPK and NF-B activation are involved in the EBV-mediated upregulation of TNF-␣ and IL-6 production that, in turn, induces IDO expression in MDM cells.
IDO produced by EBV-MDM cells suppresses the proliferation of CD4
؉ and CD8 ؉ T cells and impairs the cytolytic activity of CD8 ؉ T cells. To investigate whether the IDO produced by EBV-MDM cells can suppress the proliferation of T cells, CD4 ϩ and CD8
ϩ T cells isolated from peripheral blood mononuclear cells (PBMCs) were assessed by a standard thymidine incorporation assay. The culture medium from EBV-infected MDMs or MDMs that were not infected with EBV were harvested as conditioned medium (CM). CD4 ϩ and CD8 ϩ T cells were cultured in these CMs under anti-CD3/CD28 MAb stimulation. The levels of both CD4 ϩ and CD8 ϩ T cell proliferation were significantly lower in CM from EBV-infected MDMs than in that from uninfected MDMs (Fig. 7A and B ). Next, we tested whether the observed effects of the CM from EBV-infected MDMs on CD4 ϩ and CD8 ϩ T cell proliferation rates were related to functional IDO enzyme activity. The specific IDO inhibitor 1-methyl-L-tryptophan (1-MT) was used to block enzyme activity. As shown in Fig. 7C , CM from EBV-infected MDMs had IDO enzyme activity, whereas CM from uninfected MDMs had almost undetectable IDO enzyme activity. In addition, the functional IDO enzyme activity in 1-MTtreated CM from EBV-infected MDMs was dramatically inhibited by 1-MT. When exposed to the 1-MT-treated CM of EBV-infected MDMs, the proliferation of CD4 ϩ and CD8 ϩ T cells was almost completely restored by the addition of 1-MT (Fig. 7A and  B) . Taken together, the data indicate that the medium collected from IDO-positive EBV-infected MDMs suppressed CD4 ϩ and CD8 ϩ T cell proliferation in vitro. To investigate whether IDO produced by EBV-MDMs has an effect on the cytolytic activity of EBV-specific CD8 ϩ T cells, a standard 51 Cr release assay was conducted by using autologous EBV-transformed lymphoblastoid cell lines (EBV LCLs) as targets and EBV-specific CD8 ϩ T cells as effectors. EBV-specific CD8 ϩ T cells, generated from the expanded bulk CTLs by stimulation with ␥-irradiated (40 Gy) autologous EBV LCLs, lysed the target cells at different E/T ratios when exposed to CM from MDMs (MDM-CM), whereas the lysis rate was remarkably reduced when the T cells were exposed to CM from EBV-MDMs. The cytolytic activity of EBV-specific CD8 ϩ T cells was effectively restored when exposed to CM from EBV-MDM cells in the presence of 1-MT (Fig.  7D) . These results suggest that the inhibition of CD8 ϩ T cellmediated cytotoxicity is attributed to IDO created by EBV-MDM, and 1-MT can abrogate this effect. These findings provide a potential role for the IDO produced by EBV-MDMs in impairing CD8
ϩ T cell cytotoxic function.
DISCUSSION
Our previous study revealed that IDO expression in NPC cells resulting from IFN-␥ induction contributes to local immune tolerance in NPC (17) . In the present study, higher IDO levels were observed in the tumor stroma than in the NPC tumor cells them- selves. Given that viral infection can induce IDO expression in macrophages and that EBV-infected macrophages have been observed in NPC tissues, we then asked whether EBV infection of macrophages can induce IDO expression. Indeed, we found that EBV infection does induce IDO expression in MDMs but that irradiated EBV cannot. These data suggested that EBV infection is a potent inducer of IDO expression in MDMs.
In most cell types, IDO is induced in response to specific inflammatory stimuli. IFN-␥ represents the principal IDO inducer, and other inflammatory stimuli also induce IDO, including TNF-␣, IL-6, IL-1␤, and lipopolysaccharide (LPS), although markedly less than IFN-␥ (26) (27) (28) (29) . In the present study, TNF-␣ synergized with IL-6 to mediate IDO induction in EBV-MDMs and did not necessarily require the synthesis of IFN-␥. In line with our results, several microbial infections of MDMs have been reported to upregulate IDO expression in a TNF-␣-dependent manner but not in an IFN-␥-dependent manner, including HIV, West Nile virus (WNV), Haemophilus ducreyi, and Listeria monocytogenes infections (20, (30) (31) (32) . Synergistic activation of IDO by IL-1␤, TNF-␣, and IL-6 in human monocytic THP-1 cells exposed to LPS was reported previously (28) . Recently, IL-6 was shown to directly upregulate IDO expression in both Neuro-2a cells and an organotypic hippocampal tissue culture (33) . In addition, our data indicate that a combination of anti-TNF-␣ and anti-IL-6 antibodies did not completely abolish the IDO production induced by EBV infection, supporting the possible involvement of additional molecules.
TNF-␣-mediated activation of IDO through the MAPK/p38 and NF-B pathways has been reported for microbial infections (29) (30) (31) (32) 34) . Our data indicate that EBV induces IDO expression in response to TNF-␣ and IL-6 stimuli in MDMs dominantly though the activation of the MAPK/p38 and NF-B pathways. These results are consistent with previous studies that described HIV-induced IDO expression in dendritic cells and WNV-in- duced IDO expression in MDMs that predominantly depended on the activation of the MAPK/p38 and NF-B pathways (20, 30) . It has been confirmed that EBV infection activates the PI3K, JNK, and MAPK/p38 pathways and both the canonical and noncanonical NF-B signaling pathways (35) (36) (37) . Activation of the p38, JNK, ERK, and NF-B pathways leads to the production of IDO-inducing cytokines such as TNF-␣ and IL-6, which act in an autocrine manner to stimulate the MAPK and NF-B pathways. The MAPK and NF-B pathways contribute to IDO induction indirectly by promoting the production of TNF-␣ and directly by regulating IDO gene promoter activity, in which transcriptional factors, such as AP-1, NF-B, and NF-IL-6, are known to be activated by TNF-␣ and IL-6 (28) .
IDO expression in APCs and tumor cells can potently inhibit the immune response (38, 39) . It is therefore plausible that active IDO, expressed in MDMs after EBV infection, acts to create an immunosuppressive microenvironment. This mechanism may be one of the mechanisms by which NPC cells evade the immune response. Our data show that exposure to the microenvironment created by IDO-positive MDM cells severely suppressed both CD4 ϩ and CD8 ϩ T cell proliferation. These results favor a model describing the proliferation arrest of T cells by IDO (39) . In addition, we have presented evidence that the exposure to IDO-expressing CM from EBV-MDMs dramatically weakened the cytolytic function of CD8 ϩ T cells, derived from PBMCs, against target cells. In accordance with our observations, Liu et al. reported that in an experimental rat lung allograft model, IDO creates a local microenvironment that leads to not only a reduction in the numbers of CD8 ϩ tumor-infiltrating lymphocytes (TILs) but also the loss of the cytotoxic activity of the CD8 ϩ effector T cells toward their target cells (40) . The impaired cytotoxic function observed for IDO-treated CD8 ϩ T cells was accompanied by defects in the production of granule cytotoxic proteins, including perforin and granzymes A and B. Moreover, IDO leads to an impaired bioenergetic condition in active CD8 ϩ T cells via the selective inhibition of complex I in the mitochondrial electron transfer chain (40) . Our previous study also showed that exposure to the milieu created by IDO-positive tumor cells, including NPC cells and esophageal tumor cells, significantly impaired lymphocytes against target tumor cells (17, 41) . Although IDO was induced by tumor cells and stromal macrophages in NPC tissue through different mechanisms, the production of IDO from both of them together con- tributed to the immune-suppressive microenvironment, which might downregulate anti-EBV or antitumor T cell responses, leading to EBV persistence or tumor immune evasion. However, further studies are needed to elucidate the exact mechanisms by which IDO expression in EBV-infected MDMs reduces the cytotoxicity of CD8 ϩ T cells. Taken together, these findings indicate that TNF-␣ and IL-6 are upregulated by MDMs in response to EBV infection and that these two cytokines synergistically mediate the induction of IDO expression. EBV-induced IDO expression in MDMs is mediated largely by the p38/MAPK and NF-B pathways. The activation of IDO in response to EBV infection of MDMs could be a key event in creating an immunosuppressive microenvironment by suppressing the proliferation of T cells and impairing the cytotoxic function of CD8 ϩ T cells. Although the precise role of tumoral IDO in EBV-MDMs remains to be elucidated, our findings suggest that blocking IDO activity may provide a means of restoring host antivirus and antitumour immunity in the treatment of NPC.
